Biodexa Pharmaceuticals Plc
BDRX· Nasdaq
BDRXBiodexa Pharmaceuticals Plc
Who holds Biodexa Pharmaceuticals Plc, from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 14.8K | −84.8% | $43.1K | 0.1% | Aug 14, 2026 |
| GAMMA Investing LLC | 1.2K | −91.3% | $3.5K | 0.1% | Jul 7, 2026 |
| Allied Private Wealth LLC | 489 | — | $1.3K | 0.1% | Jul 9, 2026 |
| SBI Securities Co., Ltd. | 29 | −80.8% | $84 | 0% | Jul 23, 2026 |
| UBS Group AG | 25 | −80.3% | $73 | 0% | Aug 13, 2026 |
| Hilton Head Capital Partners, LLC | 6 | −80.0% | $17 | 0% | Jul 27, 2026 |
| Caitong International Asset Management Co., Ltd | 5 | +400.0% | $15 | 0% | Aug 5, 2026 |
| Rhumbline Advisers | 3 | −84.2% | $8 | 0% | Aug 12, 2026 |
